|
| |
| Free Weekly Newsletter | Post a Question on this Site |
| Home | About |
Daily Program | Lifestyle Tips | Why VRP? | Order Products | Checkout |
Account Information | Security |
|
· · |
Too much zinc increases the risk of prostate cancer Men who take too much zinc may be raising their prostate cancer risk, said U.S. researchers on Tuesday. Compared with nonusers, men who took more than 100 milligrams (mg) a day of zinc supplements had more than twice the risk of advanced prostate cancer, the team at the U.S. National Cancer Institute found. These levels are far above the recommended 15 mg of zinc a day. However, in the United States, 10 percent of men who take zinc supplements take two to three times more than this. Zinc supplements are popular for, among other things, their alleged benefit in preventing or reducing the severity of colds. Zinc builds up in the prostate, a gland involved in semen production. Prostate cancer is the second-most common cancer among U.S. men after skin cancer. It kills nearly 30,000 men a year. Dr. Michael Leitzmann of the NCI and colleagues looked at surveys filled out by 46,974 men taking part in a broad-reaching and ongoing study of health professionals. Writing in the Journal of the National Cancer Institute, they said they found men who took more than 100 mg a day of zinc doubled their risk of advanced prostate cancer, as did men who took the supplements for 10 years or more. Dr. Cinque's comments: I know that many men take zinc because they think it's good for the prostate. Zinc is accumulated by the prostate gland, and it is concentrated in the prostatic secretion. Zinc is also thought to enhance sexual functioning, and many libido enhancement products contain zinc. Zinc lozenges are used to fight the common cold virus. However, enough is enough; it has been known for a long time that excessive zinc is harmful. The Extend Core multi from VRP that I take contains only 15 mg. zinc, which is the RDA. I know of no good reason to take more than that. E-mail to a friend Next Article |